Literature DB >> 33598428

Value of 11C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases.

Shuoming Zhou1, Hongliang Fu2, Changming Liu3, Ziqiang Zhu1, Jiabin Zhang3, Wubin Weng3, Jian Kang1, Qiang Liu1.   

Abstract

PURPOSE: The most common disadvantage of 11C-choline positron emission tomography and computed tomography (PET/CT) in diagnosing early-stage prostate cancer (PCa) is its poor sensitivity. In spite of many efforts, this imaging modality lacks the ideal parameter of choline metabolism for the diagnosis of PCa, and the single metabolic parameter, that is, maximal standardized uptake value (SUVmax), based on this imaging modality is insufficient. 11C-choline PET/CT-based multi-metabolic parameter combination can help break this limitation.
MATERIALS AND METHODS: Before surgery, SUVmax of choline, which is the most common metabolic parameter of 11C-choline PET/CT, mean standardized uptake value (SUVmean), prostate-to-muscle (P/M) ratio, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from 74 patients with histologically proven PCa were quantified. A total of 13 patients with focal chronic prostatitis without severe features and 30 patients with benign prostate hyperplasia were used for comparison. Univariable and multivariable analyses were performed to compare the patient characteristics and metabolic parameters of 11C-choline PET/CT. The performance of single parameters and the combination of parameters were assessed by using logistic regression models.
RESULTS: The comparable c-statistics, which mean the area under the ROC curve in the logistic regression model, of SUVmax, SUVmean, and P/M ratio are 0.657, 0.667, and 0.672, respectively. The c-statistic significantly rose to 0.793 when SUVmax and SUVmean were combined with the P/M ratio. This parameter combination performed the best for PCa cases with all biochemical recurrence risks and for PCa patients grouped by different risk. The greatest improvement over a single parameter, such as P/M ratio, was noted in the group of low-risk PCa, with values of 0.535 to 0.772 for the three-parameter combination. And in the histopathological level, the Ki-67 index is positively correlated with the P/M ratio (r=0.491, p=0.002).
CONCLUSION: P/M ratio is a more ideal parameter than SUVmax as a single parameter in early-stage PCa diagnosis. According to our data, the combination of SUVmax, SUVmean, and P/M ratio as a composite parameter for diagnosis of early stage PCa improves the diagnostic accuracy of 11C-choline PET/CT.
Copyright © 2021 Zhou, Fu, Liu, Zhu, Zhang, Weng, Kang and Liu.

Entities:  

Keywords:  11C-choline; benign prostate diseases; parameter; positron emission tomography and computed tomography; prostate cancer

Year:  2021        PMID: 33598428      PMCID: PMC7882704          DOI: 10.3389/fonc.2020.600380

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  24 in total

Review 1.  Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.

Authors:  Michael S Hofman; Amir Iravani; Tatenda Nzenza; Declan G Murphy
Journal:  Urol Clin North Am       Date:  2018-06-15       Impact factor: 2.241

2.  Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer.

Authors:  Matthias Eiber; Isabel Rauscher; Michael Souvatzoglou; Tobias Maurer; Markus Schwaiger; Konstantin Holzapfel; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-12       Impact factor: 9.236

Review 3.  Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.

Authors:  Gladell P Paner; Walter M Stadler; Donna E Hansel; Rodolfo Montironi; Daniel W Lin; Mahul B Amin
Journal:  Eur Urol       Date:  2018-01-09       Impact factor: 20.096

4.  Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy.

Authors:  Takako Yamaguchi; Jin Lee; Hiroji Uemura; Takeshi Sasaki; Nobukazu Takahashi; Takashi Oka; Kazuya Shizukuishi; Hisashi Endou; Yoshinobu Kubota; Tomio Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-15       Impact factor: 9.236

5.  Prostate cancer detection is also relevant in low prostate specific antigen ranges.

Authors:  Marcos Lujan; Alvaro Paez; Elena Miravalles; Inmaculada Fernandez; Luis Llanes; Antonio Berenguer
Journal:  Eur Urol       Date:  2004-02       Impact factor: 20.096

6.  Correlation of ¹⁸F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer.

Authors:  Bo Han; Shan Lin; Li-Juan Yu; Rui-Zhi Wang; Yan-Ying Wang
Journal:  Nucl Med Commun       Date:  2009-11       Impact factor: 1.690

7.  Standardizing evaluation of sarcoma proliferation- higher Ki-67 expression in the tumor periphery than the center.

Authors:  Josefin Fernebro; Jacob Engellau; Annette Persson; Anders Rydholm; Mef Nilbert
Journal:  APMIS       Date:  2007-06       Impact factor: 3.205

8.  Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.

Authors:  Hubert Vesselle; Alexander Salskov; Eric Turcotte; Linda Wiens; Rodney Schmidt; C Diana Jordan; Eric Vallières; Douglas E Wood
Journal:  J Thorac Oncol       Date:  2008-09       Impact factor: 15.609

9.  Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer.

Authors:  S Schwarzenböck; M Souvatzoglou; B J Krause
Journal:  Theranostics       Date:  2012-03-15       Impact factor: 11.556

10.  11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series.

Authors:  Laure Michaud; Karim A Touijer; Audrey Mauguen; Michael J Zelefsky; Michael J Morris; Serge K Lyashschenko; Jeremy C Durack; John L Humm; Wolfgang A Weber; Heiko Schöder
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 11.082

View more
  2 in total

1.  18F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer.

Authors:  Shuoming Zhou; Tiantian Liu; Ziqiang Zhu; Lin Zhang; Subo Qian; Hongliang Fu; Qifeng Cao; Jian Kang
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

2.  Can Tumour Volume Percentage in Radical Prostatectomy Predict Cancer Biochemical Recurrence? Determining a Cut-off Point and Composite Risk Factors Approach.

Authors:  Ahmad Alenezi; Mohamed Ismail; Christopher Eden
Journal:  Res Rep Urol       Date:  2021-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.